As new therapies come to market for pediatric acute myeloid leukemia, there will be a lot of questions to answer regarding dosing and where these drugs are used in the patient journey, said Sarah Tasian, MD, attending physician in the Division of Oncology at Children’s Hospital of Philadelphia.
As new therapies come to market for pediatric acute myeloid leukemia, there will be a lot of questions to answer regarding dosing and where these drugs are used in the patient journey, said Sarah Tasian, MD, attending physician in the Division of Oncology at Children’s Hospital of Philadelphia.
Transcript
What challenges do you expect we will face as new antibody-based and cellular immunotherapies come to market to treat children with acute myeloid leukemia?
I think a lot of it is just simply dose finding, you know, what is the appropriate dose? What is the safe and tolerable dose for a child? Who certainly, I think, have the benefit that children tolerate things a lot better sometimes than adults do, and I think in pediatric oncology, we tend to also be pretty risk tolerant in a multiple relapse situation.
I think the other major challenge will be understanding with all of these new immunotherapies on the market, where do we best place them? You know, are these best reserved for children with secondary rate of relapse? First relapse? Primary chemotherapy refractory? And I think we're also going to need a variety of immunotherapies against different targets, because childhood AML is so genetically and even phenotypically heterogeneous, and one size will not fit all. And so I think we're really have to understand the potency of these different modalities, the relative specificity of some of these targets, but I think the biggest challenge will be now that we have the benefit of having access to a lot of these new therapies, you know, where do we best place them to really maximize benefit for our young patients?
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen